Abstract
Outpatient parenteral antimicrobial therapy (OPAT) is an established treatment option for patients with a variety of infections who require a period of intravenous therapy, are clinically stable, and do not require continuous monitoring. Many patients with fungal infections require prolonged therapy due to resistance or intolerance to oral antifungal agents. Despite the widespread use of OPAT by infection specialists, antifungal agents appear infrequently used in this setting. We suggest that with appropriate patient selection, patients with fungal infections could successfully be treated on OPAT. This article is protected by copyright. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 196-203 |
| Number of pages | 8 |
| Journal | Mycoses |
| Volume | 62 |
| Issue number | 3 |
| Early online date | 30 Nov 2018 |
| DOIs | |
| Publication status | Published - Mar 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- OPAT
- antifungal
- parenteral antifungal therapy
- invasive candidosis
- patient safety
- outpatient parenteral antimicrobial therapy
ASJC Scopus subject areas
- Infectious Diseases
- Dermatology
Fingerprint
Dive into the research topics of 'Can Intravenous Antifungal therapy be safely used in the Outpatient Parenteral Antimicrobial Therapy (OPAT) setting?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver